Results of Operations and Financial Condition. On August 3, 2026, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the second quarter ended June 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934,…

Chief Legal Officer & Corporate Secretary — Jason L. Groves, Esq.: Mr. Groves tendered his resignation from the Company.

The filing pertains to stockholder approval of an amended and restated share incentive plan, not a management change.

Results of Operations and Financial Condition. On May 4, 2026, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the first quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934, as…

Entry into a Material Definitive Agreement. On March 19, 2026, Medifast, Inc. (the "Company") and Steamboat Capital Partners LLC and certain of its related persons ("Steamboat") entered into a Cooperation Agreement (the "Cooperation Agreement"). Under the terms of the Cooperation Agreement, the Company agreed to nominate the following persons for election to the Board of Directors of the Company (the "Board") at the 2026 Annual Meeting of Stockholders of the Company (the "2026 Annual Meeting"…

Director: The filing describes routine board elections or designations without any significant management changes.

Results of Operations and Financial Condition. On February 17, 2026, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities an…

Chief Business Operations Officer — Anthony Tyree: Mr. Tyree departed from his position as Chief Business Operations Officer.

Results of Operations and Financial Condition. On November 3, 2025, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the third quarter ended September 30, 2025. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of…

Results of Operations and Financial Condition. On August 4, 2025, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the second quarter ended June 30, 2025. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934,…

The excerpt is incomplete and does not provide specific details about the management change.

Results of Operations and Financial Condition. On April 28, 2025, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the first quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934,…

Results of Operations and Financial Condition. On February 18, 2025, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities an…

Termination of a Material Definitive Agreement. On October 30, 2024, Medifast, Inc. (the "Company") terminated its Credit Agreement, dated as of April 13, 2021, among the Company, certain of its subsidiaries party thereto, the lenders party thereto, and with Citibank, N.A., as administrative agent, as amended on May 31, 2022 (the “Credit Agreement”). The Credit Agreement provided, among other things, for a secured revolving credit facility in the principal amount of up to $225 million with a…

Results of Operations and Financial Condition. On November 4, 2024, the Company issued a press release announcing its earnings for the third quarter ended September 30, 2024. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934, as amended (…

Results of Operations and Financial Condition. On August 5, 2024, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the second quarter ended June 30, 2024. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934,…

The filing describes an amendment to the company's share incentive plan and does not involve any changes in management or board composition.

Results of Operations and Financial Condition. On April 29, 2024, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the first quarter ended March 31, 2024. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities and Exchange Act of 1934,…

Results of Operations and Financial Condition. On February 20, 2024, Medifast, Inc. (the "Company") issued a press release announcing its earnings for the fourth quarter and fiscal year ended December 31, 2023. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be "filed" for any purpose, including for the purpose of Section 18 of the Securities an…

Other Events. On December 13, 2023, Medifast, Inc. (the "Company") issued a press release announcing (i) that it, through and certain of its wholly owned subsidiaries entered into a collaboration agreement with LifeMD, Inc. (Nasdaq: LFMD) and (ii) an adjustment to the Company's capital allocation policy. The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On November 6, 2023, Medifast, Inc. issued a press release announcing its earnings for the third quarter ended September 30, 2023. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (…

Regulation FD Disclosure. On September 26, 2023, Medifast, Inc. (the "Company") attended an investor meeting, during which management of the Company discussed its previously disclosed Fuel for the Future program, and inadvertently shared the Company's internal target, that was established at the beginning of 2023, of anticipated flat revenue growth for Fiscal Year 2024, which could be perceived as providing guidance. There was no intention to provide 2024 guidance, as the Company has not yet…

Other Events. On September 7, 2023, Medifast, Inc. (the "Company") issued a press release announcing the declaration of a cash dividend by the Company's Board of Directors. The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On August 7, 2023, Medifast, Inc. issued a press release announcing its earnings for the second quarter ended June 30, 2023. A copy of the Press Release is being furnished as Exhibit 99.1 attached hereto and is incorporated by reference herein. This information is being furnished in this report and shall not be deemed to be “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E…

Other Events. On June 15, 2023, Company issued a press release announcing the declaration of a cash dividend by the Company's Board of Directors. The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated by reference herein.